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Introduction {#sec1}
============

G protein-coupled receptors (GPCRs) are a large family of cell surface receptors that regulate a multitude of biological processes in response to a diverse array of stimuli and they are important drug targets. The class B/Secretin family GPCRs in humans include 15 receptors that are activated by diverse neuropeptides, peptide paracrine factors, and peptide endocrine hormones ([@bib14]). These receptors are less well understood than the larger class A/Rhodopsin family, despite their physiological and clinical importance. Class B GPCRs comprise an extracellular domain (ECD) of about 120 amino acids in addition to the 7-transmembrane (7TM) domain in the membrane. The ECD has an N-terminal α-helix and a set of β sheets held together by three disulfide bonds ([@bib1]). Peptides bind class B GPCRs via a "two-domain" model whereby their C-terminal region binds the ECD and their N-terminal region binds and activates the 7TM domain. Crystal structures are available for class B GPCR ECDs with bound peptides related to PTH, CRF, GIP, and GLP-1 ([@bib26; @bib28; @bib31; @bib32; @bib30; @bib40; @bib42]) and a consensus has emerged from these studies. The peptides bind as extended α helices to the same region of the receptor, in a groove between the N and C termini of the isolated ECDs. For PTH, GIP, and GLP-1 families, the peptides are closest to the N terminus; for the CRF-related peptides, they are displaced to be closer to the C terminus.

Although this model of binding is valid for several class B GPCRs, it cannot apply to all class B receptors. In particular, there are problems understanding the binding of members of the calcitonin (CT) family of peptides; calcitonin gene-related peptides alpha and beta (αCGRP, βCGRP), adrenomedullin (AM), adrenomedullin 2/intermedin (AM2), amylin (Amy), and CT ([@bib15; @bib34]). These C terminally amidated peptides have a range of actions including neurogenic inflammation (CGRP), vasodilation/cardioprotection (CGRP, AM, and AM2), and regulation of blood and lymphatic vascular development (AM), nutrient intake and blood glucose (Amy), and bone turnover (CT). CGRP antagonists showed promise for the treatment of migraine and AM may be of value for the treatment of cardiovascular disorders ([@bib8; @bib16]). An Amy analog is used to treat insulin-dependent diabetes patients ([@bib9]) and CT has been long used to treat bone disorders ([@bib35]).

CGRP, AM, and AM2 binding to their cognate class B receptor, the calcitonin receptor-like receptor (CLR), is dependent on association of CLR with one of three accessory membrane proteins that determine ligand selectivity; receptor activity-modifying proteins (RAMPs) 1, 2, or 3 ([@bib15; @bib21]). RAMPs have an ECD of about 100 amino acids and a single TM segment ([@bib27]). CLR:RAMP1 is a CGRP receptor, CLR:RAMP2 preferentially recognizes AM and is called the AM~1~ receptor, and CLR:RAMP3 binds both AM and AM2 with high affinities and is called the AM~2~ receptor. Amy by itself has a low affinity for the class B CT receptor (CTR); however, when CTR associates with any of the RAMPs, its affinity for Amy is markedly increased ([@bib7; @bib34]). CTR alone is the receptor for CT. Thus, the RAMPs profoundly alter the behavior of CLR and CTR. Although RAMPs are best characterized for their effects on CLR/CTR, they also interact with several other class B GPCRs and with certain class A/Rhodopsin and class C/Glutamate family GPCRs, making it particularly important to understand the molecular basis for RAMP actions ([@bib4; @bib19; @bib47]). RAMPs provide an excellent opportunity to explore how accessory membrane proteins can modulate GPCR pharmacology.

Crystal structures are available for ligand-free and small molecule antagonist-bound CLR:RAMP1 and ligand-free CLR:RAMP2 ECD complexes, but these provide little insight into how peptides bind or how RAMPs determine selectivity ([@bib18; @bib41]). Extensive mutagenesis on the RAMPs ([@bib36]) only provided clear evidence for the involvement of one RAMP residue (RAMP1 W84) in the binding of CGRP and two residues (RAMP2 F111 and E101) for AM binding ([@bib23; @bib45]). It has not been possible to interpret these data mechanistically. A further complication is that it appears unlikely that CGRP and AM bind as extended helices as seen with other class B peptide ligands; there is evidence that only a small portion of these peptides form α helices and that at their C termini, there are one or more turn structures ([@bib5; @bib6; @bib29; @bib44]). Consequently, the mechanism of RAMP action and the mode of binding of CT family peptides remain unknown. Here, we describe high-resolution crystal structures of CGRP analog-bound CLR:RAMP1 and AM-bound CLR:RAMP2 ECD heterodimers that reveal bound peptide conformations starkly different from other class B GPCR peptide ligands, explain how RAMPs determine peptide selectivity, and provide molecular templates to guide drug development targeting CLR:RAMP complexes.

Results {#sec2}
=======

Engineering CLR:RAMP ECD Complexes for Crystallization {#sec2.1}
------------------------------------------------------

We previously reported a tethered fusion protein approach to engineer the CLR:RAMP1 and CLR:RAMP2 ECD complexes for crystallization ([@bib22]), inspired by previous successes using maltose binding protein (MBP) as a "crystallization module" for class B GPCR ECDs ([@bib17; @bib26; @bib31; @bib32; @bib33; @bib30]). MBP-RAMP1 or MBP-RAMP2 ECD-CLR ECD fusion proteins in which the two ECDs were covalently tethered with a flexible (Gly-Ser)~5~ linker were designed to ensure complex stability and enforce 1:1 CLR:RAMP stoichiometry. The tethered RAMP1-CLR ECD fusion was a monomer, whereas the tethered RAMP2-CLR ECD fusion purified as a dimer, but the physiological relevance of oligomerization is unknown. Both proteins selectively bound their respective peptides but failed to yield crystals in the presence of peptides.

We reasoned that tether flexibility and oligomerization of the AM~1~ receptor ECD complex hindered the crystallization efforts. We produced new constructs with a (Gly-Ser-Ala)~3~ tether designed to decrease flexibility and we identified a single amino acid substitution in the RAMP2 ECD, L106R, which prevented dimerization of the tethered RAMP2-CLR fusion protein ([Figure S1](#mmc1){ref-type="supplementary-material"}A) by disrupting a putative oligomerization interface identified by examining crystal packing in the ligand-free CLR:RAMP2 ECD structure ([@bib18]). The monomeric RAMP2 L106R-tethered construct retained selectivity for AM over CGRP and bound AM(22-52)NH~2~ essentially identical to the wild-type tethered fusion in an AlphaScreen competition binding assay (IC~50~ ∼5--15 μM) ([Figures S1](#mmc1){ref-type="supplementary-material"}B, S1C, and S1H). In a cell-based cAMP signaling assay the full-length AM~1~ receptor with RAMP2 \[L106R\] exhibited wild-type response to AM ([Figure S1](#mmc1){ref-type="supplementary-material"}D; [Table S4](#mmc1){ref-type="supplementary-material"}). High-quality crystals of MBP-RAMP2 ECD \[L106R\]-(GSA)~3~-CLR ECD grown in the presence of AM(25-52)NH~2~ were readily obtained ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Crystals of MBP-RAMP1 ECD-(GSA)~3~-CLR ECD grown in the presence of CGRP(20-37)NH~2~ diffracted poorly (data not shown); fortunately, high-quality crystals were obtained in the presence of a high-affinity CGRP analog CGRP(27-37)NH~2~ \[D31, P34, F35\] ([@bib39]) ([Figure S1](#mmc1){ref-type="supplementary-material"}F). In the competition assay, the CGRP receptor crystallization construct was selective for CGRP over AM and bound the CGRP analog with higher affinity (IC~50~ ∼0.46 μM) than CGRP(8-37)NH~2~ (IC~50~ ∼2 μM) ([Figure S1](#mmc1){ref-type="supplementary-material"}G). The CGRP analog also bound the AM~1~ receptor crystallization construct with higher affinity than wild-type CGRP but was still lower affinity than AM ([Figure S1](#mmc1){ref-type="supplementary-material"}H). The crystallized proteins thus exhibited peptide selectivity consistent with the intact receptors. The peptides in both crystal forms are antagonist fragments that lack the N-terminal 7TM domain-activating region ([Figure S1](#mmc1){ref-type="supplementary-material"}I). The CGRP analog will hereafter be referred to as CGRPmut.

Structures of the CGRPmut-Bound CLR:RAMP1 and AM-Bound CLR:RAMP2 ECD Heterodimers {#sec2.2}
---------------------------------------------------------------------------------

Diffraction data for the CGRPmut- and AM-bound receptor complexes were collected to resolutions of 2.5 and 1.8 Å, respectively ([Table 1](#tbl1){ref-type="table"}). The structures were solved by molecular replacement (MR) and refined to good *R*~*work*~ and *R*~*free*~ values ([Table 1](#tbl1){ref-type="table"}). Three copies of the tethered CGRP receptor fusion and one copy of the tethered AM~1~ receptor fusion were present in the asymmetric units. Molecule A (Mol A) of the CGRPmut-bound structure had the best electron density and lowest B-factors ([Table 1](#tbl1){ref-type="table"}); unless otherwise noted the figures use Mol A. The peptide-bound structures are shown in [Figures 1](#fig1){ref-type="fig"}A and 1B. The *mF*~*o*~*-DF*~*c*~ electron density maps for the rebuilt MR models showed clear, unambiguous density for CGRPmut and AM ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2C). MBP sits over the bound peptides, but it does not appear to alter their binding ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2D). The final models include CGRPmut residues 27--37 and AM residues 35--52 (residues 25--34 were disordered) and the majority of the tethered fusion proteins other than the tethers and ∼20 residues at the C terminus, which were disordered ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2D). The tethers appeared to be longer than necessary, making it unlikely that they altered RAMP-CLR interactions.

CGRPmut and AM occupy similar positions near CLR loops 2, 3, and 4; only their C termini are in proximity to the RAMPs ([Figures 1](#fig1){ref-type="fig"}A and 1B). Strikingly, CGRPmut adopts a receptor-bound conformation devoid of secondary structure. Receptor-bound AM lacks secondary structure other than one α-helical turn. Shared turn structures near the peptide C termini similarly position the C-terminal residues adjacent to α2 and the α2-α3 loop of the RAMPs. CGRPmut and AM occupy the same face of the CLR ECD as observed for other class B GPCRs with their positions more similar to that of CRF than PTH ([Figure 1](#fig1){ref-type="fig"}C). Helix-breaking Pro residues are prevalent in the CGRP, AM, and AM2 sequences and the four residue segment prior to the C-terminal residue contains turn-favoring Pro or Gly residues, consistent with the observed peptide conformations ([Figure 1](#fig1){ref-type="fig"}D). The structures are consistent with our knowledge of the architectures of the intact receptor complexes. The ECDs are oriented such that their C termini could continue toward the membrane with a similar number of residues between the termini visible in the structures and the predicted start of the TM segments (∼17 residues for CLR and ∼8 for the RAMPs). The peptides are oriented such that their N termini containing the receptor-activating regions would be directed toward the 7TM domain.

CGRPmut and AM primarily contact CLR, but key RAMP contacts are also formed ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}). Two key features of the peptide-binding sites are a hydrophobic patch extending from the base of CLR loop 4 to loop 3 and a pocket extending from the base of CLR loop 4 to loop 2 and the RAMPs ([Figure 2](#fig2){ref-type="fig"}). The CLR W72 bulge, previously called the "Trp shelf" ([@bib41]), demarcates patch and pocket. The patch comprises the Trp shelf, F92, F95, and Y124. The pockets comprise the Trp shelf, D70, G71, W121, T122, Y124, and RAMP1 W84 and P85 in the CGRP receptor ([Figures 2](#fig2){ref-type="fig"}A and 2B) or RAMP2 R97, E101, E105, and P112 in the AM~1~ receptor ([Figures 2](#fig2){ref-type="fig"}C and 2D). CGRPmut G33-A36 and AM S48-G51 form type II β-turns that contact CLR loop 4 in part via hydrogen bonds between the turn main chain and CLR S117, R119, and W121 side chains ([Figures 2](#fig2){ref-type="fig"}B and 2D). The β-turns enable the peptide C termini to occupy their respective pockets where their amide groups hydrogen bond with the CLR T122 main chain and their C-terminal residues pack against the Trp shelf, CLR G71, and RAMP1 W84 from the α2-α3 loop, which makes hydrophobic contact with CGRPmut F37 ([Figures 2](#fig2){ref-type="fig"}A and 2B), or RAMP2 R97, E101, and E105 from α2, which hydrogen bond with AM Y52 and K46 ([Figures 2](#fig2){ref-type="fig"}C and 2D). Prior to the β-turns CGRPmut V32 and AM I47 similarly contact the patch, but moving backward thence the peptides diverge in their interactions. CGRPmut T30 forms main chain- and side chain-mediated hydrogen bonds with CLR D94 on loop 3 and contacts the patch via its side chain methyl group ([Figures 2](#fig2){ref-type="fig"}A and 2B). The single helical turn in AM enables K46 to contact the Trp shelf and pack against AM Y52 and AM P43 and A42 contact the patch ([Figures 2](#fig2){ref-type="fig"}C and 2D). AM K38-A42 form a series of main chain-mediated hydrogen bonds with the main chain of CLR loop 3 and the side chains of D94 in loop 3 and T37 on α1 ([Figure 2](#fig2){ref-type="fig"}D). For the CGRPmut-bound structure, 94% of the solvent accessible surface area (ASA) of the ECD complex buried at the interface with the peptide is from CLR (478 Å^2^) and only 6% is from RAMP1 (29 Å^2^). More ASA is buried at the interface with AM, but the majority is still from CLR, 90% (781 Å^2^), whereas RAMP2 contributes only 10% (85 Å^2^).

Comparisons to Ligand-free and Small Molecule Antagonist-Bound Structures {#sec2.3}
-------------------------------------------------------------------------

Superpositions of CGRPmut-bound and ligand-free CLR:RAMP1 complexes ([@bib41]) revealed clamp-like movement of CLR loops 3 and 4 upon CGRPmut binding, presumably mediated by the CGRPmut T30-CLR D94 interaction and β-turn contacts with CLR loop 4 including the CGRPmut F35-CLR S117 interaction ([Figures 3](#fig3){ref-type="fig"}A and 3B). CLR R119 shifts to accommodate the peptide and RAMP1 F83 rotates away from CLR loop 4 ([Figure 3](#fig3){ref-type="fig"}B). The RAMP1 position relative to CLR varies in the structures ([Figure 3](#fig3){ref-type="fig"}A), but the positions of the α2-α3 loop and W84, which contacts CGRPmut F37, remain relatively similar ([Figures 3](#fig3){ref-type="fig"}A and 3B).

The CGRPmut-bound structure explains antagonism by the CGRP receptor-selective small molecule drugs olcegepant and telcagepant. Superposition of the CGRPmut-bound and drug-bound structures ([@bib41]) indicated that olcegepant and telcagepant block key interactions of the CGRP C-terminal amide and F37 with the receptor pocket by hydrogen bonding with the CLR T122 main chain at the base of the pocket and packing of their piperidyl moieties against the Trp shelf and G71 ([Figures 3](#fig3){ref-type="fig"}C and 3D). Olcegepant also hydrogen bonds with CLR D94, thereby blocking the CGRP T30-CLR D94 interaction ([Figure 3](#fig3){ref-type="fig"}C). The position of RAMP1 relative to CLR in the peptide-bound versus drug-bound structures varies such that the drugs appear to favor RAMP1 α2 shifting closer to the small molecule binding sites ([Figure 3](#fig3){ref-type="fig"}E), presumably due to drug-RAMP1 interactions including packing against W74 ([Figures 3](#fig3){ref-type="fig"}C and 3D).

Superposition of the AM-bound and ligand-free CLR:RAMP2 complexes ([@bib18]) revealed minor CLR conformational differences involving the N-terminal region of α1 moving toward AM in the AM-bound state presumably due to AM-CLR T37 contacts ([Figure 3](#fig3){ref-type="fig"}F). CLR loops 3 and 4 do not move as in the CGRPmut-bound structure and there are no significant side-chain conformational differences at the peptide-binding site. The position of RAMP2 relative to CLR varies in the two structures ([Figure 3](#fig3){ref-type="fig"}F), but the ligand-free RAMP2 position is probably constrained by formation of the dimer of heterodimers in which the C-terminal end of RAMP2 α2 occupies the peptide-binding site of CLR from the opposing heterodimer ([Figure 3](#fig3){ref-type="fig"}G). Dimerization of the CLR:RAMP2 ECD heterodimer thus occludes the AM-binding site, which suggested that the RAMP2 L106R substitution (at the end of RAMP2 α2) was key to obtaining AM-bound crystals.

Validation of the Structures for Intact CGRP and AM~1~ Receptors in Cells {#sec2.4}
-------------------------------------------------------------------------

To validate the structures, we constructed several Ala substitution mutants in the CLR and RAMP2 ECDs, and they were analyzed for their effects on peptide-stimulated cAMP formation in COS-7 cells. For the CGRP receptor, Ala substitution of CLR W69, D70, K103, or Y91 significantly reduced CGRP potency, likely due to the structural roles of these residues ([Figure 4](#fig4){ref-type="fig"}, [Table S3](#mmc1){ref-type="supplementary-material"}). Ala substitution of CLR W72, F92, D94, F95, H114, R119, W121, T122, or Y124, which are contacted by CGRPmut in the structure, reduced potency of the full-length CGRP \>20-fold with the CLR D94A mutant being strikingly defective.

For the AM~1~ receptor, Ala substitution of CLR W72, F92, F95, W121, or Y124, which are contacted by AM in the structure, resulted in \>40-fold decreases in AM potency ([Figure 5](#fig5){ref-type="fig"}A, [Table S4](#mmc1){ref-type="supplementary-material"}). CLR D94, H114, R119, or T122 mutants were less deleterious with 4- to 9-fold decreases in AM potency. Mutation of RAMP2 E101 yielded 26-fold reduced AM potency ([Table S4](#mmc1){ref-type="supplementary-material"}; [@bib45]). Surprisingly, Ala substitution of RAMP2 R97 or E105 did not affect AM signaling potency despite their contacts with AM ([Figure 5](#fig5){ref-type="fig"}B). RAMP2 R97A/E101A and E101A/E105A double mutants had defects similar to the E101A single mutant. These data emphasize that RAMP2 E101 provides the crucial contacts to AM. The Ala substitutions did not significantly alter receptor cell surface expression levels other than reduced AM~1~ receptor expression with CLR Y124A ([Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}).

Peptide Selectivity Determinants {#sec2.5}
--------------------------------

RAMPs may confer selectivity by providing distinct contacts to the peptides, altering CLR conformation, or a combination of the two. Superposition of the CGRPmut- and AM-bound structures indicated that the RAMPs augment the peptide-binding site pocket with distinct residues from their α2-α3 loop and α2 ([Figure 6](#fig6){ref-type="fig"}A). RAMP1 W84 in the α2-α3 loop makes hydrophobic contact with the CGRPmut F37 phenyl ring. This contact would be lost in RAMP2, which has the smaller F111 at the equivalent position. RAMP2 E101 on α2 hydrogen bonds with AM K46 and Y52. The equivalent RAMP1 W74 cannot make these contacts. Two other peptide-proximal RAMP positions differ: RAMP1 F83/RAMP2 G110 on the α2-α3 loop and RAMP1 A70/RAMP2 R97 on α2 ([Figure 6](#fig6){ref-type="fig"}B). The F83/G110 position is close to CLR loop 4 and the R119 side chain that has different conformations in the two structures. RAMP2 R97, which participates in the hydrogen bond network near AM Y52, would sterically clash with a Trp at position 111. The small A70 in RAMP1 avoids a clash with W84.

The positions of RAMP1 and RAMP2 relative to CLR differ in the two structures and the RAMPs elicit subtly different CLR conformations ([Figure 6](#fig6){ref-type="fig"}A). Equivalent RAMP1/2 Cα positions at the end of α2 differ by ∼3 to 4.5 Å such that RAMP2 α2 is closer to the peptide-binding site than RAMP1 α2. A similar 3 to 4.5 Å displacement of the RAMP1/2 α3 helices is accompanied by shifts in the position of the C-terminal end of CLR α1 ([Figures 6](#fig6){ref-type="fig"}A and 6B). The RAMPs and CLR α1 appear to move somewhat as a unit relative to the remainder of CLR, which is also evident in the comparisons of the peptide-bound structures to the ligand-free and small molecule antagonist-bound structures ([Figures 3](#fig3){ref-type="fig"}A, 3E, and 3F). The subtly different CLR loop 2 positions in the structures may reflect RAMP-dependent differences at the interface with CLR α1 propagated to loop 2 via CLR W69 ([Figures 6](#fig6){ref-type="fig"}A and 6B).

To explore the contribution of RAMP binding site augmentation to selectivity, we constructed RAMP "swap" mutants in which the four variable residue positions near the peptide C termini were reciprocally exchanged between RAMP1 and RAMP2 (A70/R97, W74/E101, F83/G110, and W84/F111) and we tested their response to CGRP and AM in the cAMP assay ([Figures 6](#fig6){ref-type="fig"}C and 6D). The clearest effect was one of a modest decrease in cognate ligand potency. Accordingly, CGRP potency decreased ∼10-fold at the CGRP receptor that included the RAMP1 mutant with RAMP2 residues and AM potency decreased ∼50-fold in the AM~1~ receptor with the RAMP2 mutant that contained RAMP1 residues. Thus, swapping these RAMP residues was insufficient to exchange pharmacological profiles, but the differing RAMP1/2 positions probably complicated the experiment.

We turned to peptide swap experiments to test whether reciprocal exchanges of the C-terminal residues of minimal ECD complex-binding CGRP and AM peptides ([@bib22]) could exchange their receptor selectivity. In the competition AlphaScreen assay, CGRP(27-37)NH~2~ \[F37Y\] retained the ability to bind the CGRP receptor ECD complex ([Figure 6](#fig6){ref-type="fig"}E) and did not gain AM-like affinity for the AM~1~ receptor ECD complex ([Figure 6](#fig6){ref-type="fig"}H). CGRPmut \[F37Y\] retained CGRP receptor ECD complex binding ([Figure 6](#fig6){ref-type="fig"}F) and gained the ability to bind the AM~1~ receptor ECD complex as strongly as AM ([Figure 6](#fig6){ref-type="fig"}I). AM(37-52)NH~2~ \[Y52F\] exhibited significantly diminished binding to the AM~1~ receptor ECD complex ([Figure 6](#fig6){ref-type="fig"}J) but did not gain increased affinity for the CGRP receptor ECD complex ([Figure 6](#fig6){ref-type="fig"}G). These results suggested that the RAMP2 E101-AM Y52 hydrogen bond is a key contributor to AM~1~ receptor selectivity, whereas Phe as the peptide C-terminal residue is insufficient to confer CGRP receptor selectivity.

Discussion {#sec3}
==========

RAMPs are an important class of accessory membrane proteins that modulate GPCR pharmacology. The CGRPmut-bound CLR:RAMP1 ECD and AM-bound CLR:RAMP2 ECD structures presented here expand our understanding of the mechanisms by which peptides can bind to class B GPCRs and increase our understanding of how RAMPs enable peptide selectivity. The engineered tethered ECD fusion proteins used for crystallization exhibited the same peptide selectivity rank order as the intact receptors, which indicated that they are valid reagents for studying selective peptide binding. The purified proteins bound their respective peptides with apparent affinities in the low μM range ([Figures S1](#mmc1){ref-type="supplementary-material"}C, S1G, and S1H), which are lower than the affinities of the agonist peptides for intact receptors but typical for truncated peptides at class B GPCR ECDs ([@bib26; @bib28; @bib30]).

The oligomeric states of CLR:RAMP complexes has been a source of debate with evidence for 1:1, 2:1, and 2:2 CLR:RAMP stoichiometries ([@bib12; @bib13; @bib18; @bib22; @bib43]). Dimerization of the purified CLR:RAMP2 ECD heterodimer to form a 2:2 complex may be an artifact because the RAMP2 L106R mutation prevented oligomerization yet did not affect AM~1~ receptor function ([Figure S1](#mmc1){ref-type="supplementary-material"}). Occlusion of the AM-binding site by dimerization explains our inability to measure AM binding to the tethered RAMP2-CLR ECD fusion protein in an assay using μM receptor concentration, whereas AM binding was readily measured in an assay using nM receptor concentration where the dimeric species was likely not significantly present ([@bib22]). [@bib12] provided evidence for a homo-oligomer of CLR with a single RAMP1 as the functional CGRP receptor in cells. We cannot rule out a role for higher-order oligomerization in the function of the intact receptors, but the structures indicate that the 1:1 heterodimers are sufficient to bind peptides.

The CGRPmut and AM peptides adopted receptor-bound conformations different from typical α-helical class B GPCR peptide ligands. CGRPmut and AM are characterized by a shared turn structure that positions their C-terminal residue to occupy the pocket near the RAMP. Previous studies indicated the presence of turns in the C-terminal region of CGRP (and an absence of α-helix in this area), but how this region interacted with the receptor was unclear ([@bib6; @bib44]). Prior to the turns, the peptides diverge in their structure and interactions with CLR, but they contact the same area of CLR with little or no peptide secondary structure. NMR structures of CGRP and AM suggested that α-helix is restricted to residues 8-18/22-34 of these peptides ([@bib3; @bib5; @bib29; @bib43]) and indeed the C-terminal regions of both contain helix-breaking Pro residues ([Figure 1](#fig1){ref-type="fig"}D). Accordingly, the lack of substantial helical content in the bound peptide fragments is consistent with what is known about the structures of the full-length peptides. A turn structure and paucity of α-helicity may be a general feature of the receptor ECD-binding portions of CT family peptides.

The CGRPmut and AM binding modes are consistent with peptide mutagenesis studies. CGRP T30, V32, and F37 and the C-terminal amide were important for binding purified CLR:RAMP1 ECD ([@bib22]) and intact CGRP receptor ([@bib6; @bib39; @bib44]). Modified CGRP peptides as short as 30--37 maintained the ability to bind the receptor ([@bib6]), consistent with this region providing most of the contacts. Increased affinity of CGRPmut over that of CGRP can be explained by their differences in the turn region ([Figure 1](#fig1){ref-type="fig"}D). P34 favors β-turn formation better than S34 and F35 provides better hydrophobic contact to CLR loop 4 than K35. AM P43, K46, I47, G51, Y52, and the C-terminal amide were most critical for binding purified CLR:RAMP2 ECD and intact AM~1~ receptor, and truncation beyond residue 38 diminished binding even though the K38-V41 side chains were not important ([@bib22; @bib43]).

Mapping the receptor mutagenesis data ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}) onto the surface of the receptor structures ([Figures 7](#fig7){ref-type="fig"}A and 7B) suggests that CGRP binds in a similar manner to CGRPmut and that the structures are good models for full-length CGRP and AM binding to intact receptors. Mutation of CLR residues that form the shared binding site diminished CGRP and AM potencies, and the effects of some of the mutations were similar for both peptides (e.g., F92). Noteworthy divergent effects of several mutations support the differences in the structures. CLR D94 was far more important for CGRP action than AM, consistent with the crucial role of D94 in contacting CGRP T30 and its less important role in contacting the AM main chain. CLR R119A diminished the potency of CGRP much more than that of AM, which may reflect an important role for the different R119 conformations observed in the two structures. CLR W72A was more deleterious for AM action than CGRP, which is consistent with the greater number of AM contacts to CLR W72 as compared to CGRP.

RAMP1 W84 and RAMP2 E101 were previously identified as key residues for CGRP and AM function, respectively ([@bib23; @bib45]). These data are explained by how these residues augment the binding site pocket ([Figures 7](#fig7){ref-type="fig"}A and 7B). Apparently, packing of the CGRP F37 and AM Y52 phenyl rings against the CLR Trp shelf and G71 is insufficient for strong binding. RAMP1 W84 or RAMP2 E101 is required to complete the pocket to enable strong "anchoring" of the peptide C termini. RAMP2 R97 and E105 also augment the pocket, but the R97A and E105A mutants did not diminish AM potency. These data along with the peptide swap data indicate that the RAMP2 E101-Y52 hydrogen bond is the crucial AM anchoring contact. Ionic interactions of AM K46 and RAMP2 E101/E105 do not appear to be significant. The main role of AM K46 thus appears to be intramolecular packing against Y52 and contacting the Trp shelf.

Distinct RAMP binding site augmentation clearly contributes to peptide selectivity ([Figure 6](#fig6){ref-type="fig"}). RAMP2 E101 favors AM binding because it can hydrogen bond with Y52 and RAMP2 F111 discourages CGRP binding because it is too small to contact the F37 phenyl ring. Indeed, the F37Y swap in CGRPmut conferred strong affinity for the AM~1~ receptor ECD complex and the Y52F swap in AM(37-52)NH~2~ significantly diminished its binding. The lack of Glu at RAMP1 position 74 would disfavor strong AM binding. RAMP1 W84 enables strong CGRP binding by contacting F37, but this contact alone is apparently insufficient for selectivity because AM(37-52)NH~2~ \[Y52F\] did not gain affinity for the CGRP receptor ECD complex.

Modeling the AM-bound AM~2~ receptor ECD complex ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) suggests that RAMP3 augments the binding site as a RAMP1-2 hybrid ([Figure 7](#fig7){ref-type="fig"}C). RAMP3 E74, which is equivalent to RAMP2 E101, would favor AM binding by hydrogen bonding with Y52. RAMP3 W84, which is equivalent to RAMP1 W84, could contact the AM Y52 and CGRP F37 phenyl rings, thereby explaining diminished potency of both peptides at the AM~2~ receptor with RAMP3 W84A and why CGRP is more active at the AM~2~ receptor than the AM~1~ receptor ([@bib45]). The key RAMP residues proposed as selectivity determinants are conserved across species: W84 and a lack of Glu at position 74 in RAMP1, E101 and F or Y at position 111 in RAMP2, and E74 and W84 in RAMP3 ([Figure 7](#fig7){ref-type="fig"}D). A small amino acid is conserved at position 70 in RAMP1/3, which would avoid steric clash with W84. Notably, the lack of conservation of RAMP2 R97 and E105 is consistent with the mutagenesis data that indicated that these residues are not critical for AM signaling.

Previous RAMP single swap mutant studies supported the importance of Glu at position 74/101 as a determinant for AM selectivity. RAMP1 W74E had no effect on CGRP potency but increased AM potency at the CGRP receptor ([@bib37; @bib38]). RAMP3 E74W decreased AM potency at the AM~2~ receptor, while having a negligible effect on CGRP potency ([@bib11; @bib37; @bib38]). More extensive quadruple swap mutants in this study failed to exchange the pharmacological profiles, but these experiments are complicated by the different RAMP positions relative to CLR and variable RAMP effects on CLR conformation.

The failure of the CGRP and AM peptide C-terminal residue swaps to exchange their receptor preferences ([Figure 6](#fig6){ref-type="fig"}) strongly suggests that RAMP binding site augmentation alone is insufficient to account for selectivity. Thus, the subtle differences in CLR conformation in the two structures may also be important for selectivity. RAMP-induced changes in CLR R119 side-chain conformation and/or subtle shifting of loop 2 may sufficiently alter the pocket to favor one peptide over the other. Future studies will be required to determine to what extent such allostery contributes to selectivity. Peptide selectivity determinants may also exist in portions of the receptors that were not addressed in this study.

In summary, the structures presented here provide the first structural views of any accessory membrane protein modulating GPCR ligand binding and may provide a basis for understanding modulation of other GPCRs by accessory proteins. Our data indicate that RAMPs determine peptide selectivity of CLR through a combination of binding site augmentation and alteration of CLR conformation. It is striking that relatively minor differences in RAMP-specific peptide contacts and subtle RAMP-induced changes in CLR conformation lead to such profoundly different pharmacological profiles. Of practical value, the structures may inform rational drug design targeting CLR:RAMP complexes with clinical relevance for migraine headache and cardiovascular disorders. Lastly, the MBP-tethered ECD fusion protein approach to crystallization should facilitate structural studies of other CT family peptides bound to their respective receptor ECD complexes, which will enable a more complete understanding of how RAMPs modulate both CLR and CTR.

Experimental Procedures {#sec4}
=======================

Protein Production and Characterization and Peptides {#sec4.1}
----------------------------------------------------

Plasmid construction, mutagenesis, protein expression, purification, and the AlphaScreen peptide-binding assay were as previously described with minor modifications to the AlphaScreen assay ([@bib13; @bib22]). Synthetic peptides were from RS Synthesis, Bachem, or were synthesized in-house. Details are in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Crystallization, Structure Solution, and Homology Modeling {#sec4.2}
----------------------------------------------------------

The tethered MBP-RAMP1 ECD-CLR ECD and MBP-RAMP2 ECD \[L106R\]-CLR ECD proteins were complexed with CGRP(27-37)NH~2~ \[D31, P34, F35\] or AM(25-52)NH~2~ and crystallized with a reservoir solution of 22% PEG3350, 8% Tacsimate (pH 6.0) for the CGRP receptor complex or 19% PEG3350, 0.1 M Tris-HCl (pH 8.3), 225 mM sodium acetate, and 20% ethylene glycol for the AM~1~ receptor complex. Diffraction data collected at the APS synchrotron were processed with HKL2000 ([@bib25]) and the CCP4 suite ([@bib46]). The structures were solved by molecular replacement with Phaser ([@bib20]), rebuilt with COOT ([@bib10]), and refined with REFMAC5 ([@bib24]). Details and homology modeling are in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cell-Based Assays {#sec4.3}
-----------------

Transfection of COS-7 cells, cAMP assay, ELISA for cell surface expression, and data analysis were as previously described ([@bib2; @bib45]).

Author Contributions {#sec5}
====================

J.M.B. produced and characterized proteins, performed crystallization, collected diffraction data, and constructed CLR and RAMP mutants; C.S.W., M.A.J., and D.L.H. designed, performed, and analyzed cell-based assays for the CGRP and AM~1~ receptors; J.B., G.K., J.S., R.M.B., and D.R.P. designed and constructed CLR mutants and performed and analyzed cell-based assays for the CGRP receptor; J.S. performed RAMP3 homology modeling; M.L.W. performed peptide binding experiments; P.W.H. and M.A.B. synthesized CGRP analog; A.A.P. designed and managed the structural project, solved/refined the structures, and wrote the manuscript with D.R.P. and D.L.H.
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The accession numbers for the coordinates and structure factors reported in this paper for the AM:CLR:RAMP2 and CGRPmut:CLR:RAMP1 complexes, respectively are PDB: [4RWF](pdb:4RWF){#intref0010}, [4RWG](pdb:4RWG){#intref0015}.
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![Peptide-Bound CGRP and AM~1~ Receptor ECD Heterodimer Structures\
(A and B) CGRPmut- and AM-bound complexes in cartoon representation with disulfide bonds as sticks and secondary structure elements labeled. Peptide, CLR, and RAMP terminal residues are numbered. Peptide side chains are shown as sticks in the left images but are omitted in the right images. MBP is not shown. The color scheme is consistent throughout the figures with carbon atoms varied in color to distinguish the proteins/peptides and oxygen, nitrogen, and sulfur atoms in CPK colors.\
(C) Superpositions of the peptide-bound complexes with the PTH:PTH1R ECD (PDB: [3C4M](pdb:3C4M){#intref0025}) and CRF:CRFR1 ECD (PDB: [3EHU](pdb:3EHU){#intref0030}) structures. The receptors are shown as Cα traces and the peptides as cartoons.\
(D) Amino acid sequences of the C-terminal regions of the human CGRP, CGRPmut, AM, and AM2 peptides. The turn structure region is highlighted in gray and Pro residues are in bold. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![CGRPmut and AM Interactions with Their Receptor ECD Complexes\
(A and C) The peptide-bound structures viewed with the receptor complexes in molecular surface representation and the peptides as cartoons with side chains as sticks.\
(B and D) Detailed views with the receptors in cartoon representation and selected receptor residues and the peptides as sticks. Red dashes are hydrogen bonds. Peptide residues are labeled in (A) and (C) and receptor residues are labeled in (B) and (D). In (B), CGRPmut residues F27 and V28 are shown as lines for visualization of the CGRPmut T30-CLR D94 interaction. See also [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Comparisons of the CGRPmut- and AM-Bound Structures to Ligand-free and Small Molecule Antagonist-Bound Structures\
(A) CGRPmut-bound complexes from Mol A and Mol C were aligned with four independent ligand-free CLR:RAMP1 complexes (PDB: [3N7P](pdb:3N7P){#intref0035}) based on the CLR positions. Mol B of the CGRPmut-bound structure was omitted because crystal packing altered its conformation. Receptors are shown as Cα traces. Arrows denote the directions of loop movements upon CGRPmut binding. The double-headed arrow highlights variability in the RAMP1 position relative to CLR.\
(B) Detailed view of differences between the CGRPmut-bound and ligand-free states of the CLR:RAMP1 ECD complex. CGRPmut F27 and V28 are omitted for clarity.\
(C and D) Superposition of CGRPmut-bound and olcegepant-bound (PDB: [3N7S](pdb:3N7S){#intref0040}) (C) or telcagepant-bound (PDB: [3N7R](pdb:3N7R){#intref0045}) (D) structures aligned based on the CLR positions. The peptide and small molecules are shown as sticks.\
(E) Superpositions of the CGRPmut-bound structures with two independent olcegepant-bound complexes and a single telcagepant-bound complex based on the CLR positions. The arrow indicates the direction of movement of RAMP1 from the small molecule antagonist-bound to CGRPmut-bound states.\
(F) Superposition of the AM-bound and ligand-free (PDB: [3AQF](pdb:3AQF){#intref0050}) CLR:RAMP2 ECD structures aligned based on the CLR positions. Receptors are shown as Cα traces and selected receptor and peptide residues as sticks. Arrows indicate directions of movement from ligand-free to AM-bound states.\
(G) Putative dimer of ligand-free CLR:RAMP2 ECD heterodimers with the AM-bound CLR:RAMP2 ECD \[L106R\] heterodimer superimposed based on the CLR positions. The receptors and peptide are in cartoon representation and residues L/R106 are in space-filling representation. The arrow indicates the shift of RAMP2 in the AM-bound structure as compared to the ligand-free state. The top image is oriented similar to that in (F), right image.](gr3){#fig3}

![Validation of the CGRPmut-Bound ECD Heterodimer Structure for the Intact CGRP Receptor Transiently Expressed in COS-7 Cells\
Concentration-response curves for each of the CLR alanine substitution mutants tested with hαCGRP in cAMP signaling assays. Data are represented as mean ± SEM. See also [Table S3](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Validation of the AM-Bound ECD Heterodimer Structure for the Intact AM~1~ Receptor Transiently Expressed in COS-7 Cells\
Concentration-response curves for each of the CLR (A) or RAMP2 (B) alanine substitution mutants tested with hAM in cAMP signaling assays. Data are represented as mean ± SEM. See also [Table S4](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Peptide Selectivity Determinants for CLR:RAMP1/2 Complexes\
(A) Superposition of the CGRPmut- and AM-bound ECD heterodimers aligned based on the CLR positions. The receptors and peptides are in cartoon representation with selected residues as sticks in the left image. In the right image, the receptors are Cα traces and the peptide cartoons were omitted for clarity. Arrows indicate directions of movement of CLR α1 and loop 2 and RAMP α2 and α3 from the CGRPmut/RAMP1-bound state to the AM/RAMP2-bound state. Red dashes are hydrogen bonds.\
(B) Detailed view of the aligned CGRPmut- and AM-bound complexes with selected residues as sticks and the receptors as Cα traces. The arrow highlights the shift of the C-terminal region of CLR α1 from the CGRPmut/RAMP1- to AM/RAMP2-bound states.\
(C and D) Concentration-response curves for the CGRP and AM~1~ receptors with the RAMP1 (A70R, W74E, F83G, W84F) and RAMP2 (R97A, E101W, G110F, F111W) quadruple "swap" mutants tested with hαCGRP and hAM in cAMP assays in COS-7 cells. The cell surface expression was: RAMP1 quad 116.4 ± 5.25 (n = 4) % WT, RAMP2 quad 73.7 ± 9.52 (n = 4) % WT p \< 0.01 by one-way ANOVA followed by Dunnett's test for the RAMP2 quad mutant.\
(E--J) Competition AlphaScreen assays with purified receptor ECD heterodimer proteins and the indicated competitor "swap" peptides. (E)--(G) are for the MBP-RAMP1-(GSA)~3~-CLR-H~6~ protein with biotin-CGRP (100 nM each) and (H)--(J) are for the MBP-RAMP2\[L106R\]-(GSA)~3~-CLR-H~6~ protein with biotin-AM (100 nM each). The binding data are representative of at least three independent experiments each performed in duplicate. The error bars represent the SEM of the experiment. Determinable pIC~50~ values were as follows: (F), CGRPmut 6.79 ± 0.10 and CGRPmut \[F37Y\] 6.24 ± 0.09; (G), CGRP(8-37) 5.01 ± 0.04; (H), AM(22-52) 4.92 ± 0.16; (I), AM(22-52) 4.84 ± 0.09 and CGRPmut \[F37Y\] 4.79 ± 0.07; (J), AM(37-52) 5.00 ± 0.11.](gr6){#fig6}

![Summary of Peptide Recognition and Selectivity Determinants for CLR:RAMP1-3 Complexes\
(A and B) Structures of the CGRPmut- and AM-bound CLR:RAMP1/2 ECD heterodimers with the surface of receptor residues colored according to their effect on CGRP (A) or AM (B) signaling potency when mutated to alanine. Color coding signifies the extent of reduced signaling potency at intact receptor complexes in cells compared to wild-type as indicated by the inset legend. RAMP1 W84A data are from [@bib23] (34-fold reduced potency).\
(C) Model for RAMP3 binding site augmentation. A homology model of the AM-bound CLR:RAMP3 ECD complex ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) was superimposed with the CGRPmut-bound CLR:RAMP1 and AM-bound CLR:RAMP2 ECD structures based on the CLR positions. Only the RAMP3 subunit from the homology model is shown and RAMP2 is omitted. The receptors are shown as Cα traces and selected residues as sticks.\
(D) Amino acid sequence alignments for RAMP1-3 from the indicated species showing the α2 and α2-α3 loop regions that augment the peptide-binding site.](gr7){#fig7}

###### 

Data Collection and Refinement Statistics

                                                               MBP-RAMP1-CLR:CGRP(27-37)NH~2~ \[D31, P34, F35\]               MBP-RAMP2-CLR:AM(25-52)NH~2~
  ------------------------------------------------------------ -------------------------------------------------------------- ------------------------------
  **Data collection**                                                                                                         
                                                                                                                              
  Space group                                                  C2                                                             P2~1~2~1~2~1~
                                                                                                                              
  **Cell dimensions**                                                                                                         
                                                                                                                              
  *a*, *b*, *c*                                                172.81 Å, 104.62 Å, 136.48 Å                                   71.45 Å, 84.28 Å, 115.76 Å
  α, β, γ                                                      90°, 122.43°, 90°                                              90°, 90°, 90°
  Resolution                                                   50.0--2.45 Å (2.49--2.45 Å)[a](#tblfn1){ref-type="table-fn"}   50.0--1.76 Å (1.79--1.76 Å)
  *R*~merge~                                                   0.058 (0.647)                                                  0.068 (0.966)
  *CC*~*1/2*~                                                  (0.858)                                                        (0.525)
  *I* / σ*I*                                                   24.30 (1.76)                                                   30.13 (1.05)
  Completeness                                                 99.8% (98.6%)                                                  99.9% (98.2%)
  Redundancy                                                   4.2 (3.9)                                                      7.2 (5.0)
                                                                                                                              
  **Refinement**                                                                                                              
                                                                                                                              
  Resolution (Å)                                               50.0-2.45 Å                                                    50.0-1.76 Å
  No. reflections                                              72,185                                                         66,505
  *R*~work~ / *R*~free~                                        0.200/0.243                                                    0.157/0.200
  Protein molecules/ASU                                        3                                                              1
                                                                                                                              
  **No. atoms (Mol 1/2/3)**                                                                                                   
                                                                                                                              
  MBP                                                          2,885/2,865/2,859                                              2,898
  RAMP1 or RAMP2                                               705/657/705                                                    721
  CLR                                                          805/981/744                                                    805
  CGRP or AM                                                   86/86/75                                                       148
  Water                                                        70                                                             394
                                                                                                                              
  **B-factors (Mol 1/2/3)**                                                                                                   
                                                                                                                              
  MBP                                                          71.62/94.58/96.57                                              37.14
  RAMP1 or RAMP2                                               72.26/101.20/96.41                                             30.93
  CLR                                                          61.60/67.61/88.84                                              35.75
  CGRP or AM                                                   72.24/101.71/81.79                                             44.55
  Water                                                        52.85                                                          39.32
                                                                                                                              
  **RMS deviations**                                                                                                          
                                                                                                                              
  Bond lengths                                                 0.013 Å                                                        0.020 Å
  Bond angles                                                  1.516°                                                         1.929°
                                                                                                                              
  **Ramachandran Analysis**[b](#tblfn2){ref-type="table-fn"}                                                                  
                                                                                                                              
  Preferred regions                                            95.72%                                                         96.8%
  Allowed regions                                              4.04%                                                          3.2%
  Outliers                                                     0.24%                                                          0%

Values in parentheses are for highest-resolution shell.

As defined in COOT.

[^1]: Present address: Adaptimmune Limited, 91 Park Drive, Milton Park, Abingdon, OX14 4RY, UK

[^2]: Present address: Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK
